PolyPid Lytham Partners Fall 2026 Investor Conference

Hello, everyone, and thank you all for joining us during the Lytham Partners Fall 2026 Investor Conference. My name is Ben Shamsian, Vice President of Lytham Partners. Today, Dikla Czaczkes Akselbrad, CEO of PolyPid, will be taking us through a brief slide presentation. PolyPid trades under PYPD. Let's get started. Dikla, welcome, and I will turn the floor over to you for your presentation.

Thank you, Ben, and good day, everyone. Happy to be here and introduce you to PolyPid. PolyPid is a biopharmaceutical company in a very interesting time in the life of the company. We have a PDUFA date very soon, November 28th, for our lead product and a pipeline of product based on our proprietary technology called Kynatrix, that allow for long-acting controlled release of a drug. The technology can be customized to any API, and we have started with surgical site infection, which I'll elaborate in a minute. More than 170 patents already granted and approved around the platform and the pipeline product. Close to 90 employees. As Ben mentioned, we are traded under the symbol PYPD. What's the magic is all about? What is this Kynatrix platform? We are taking advantage of two very well-established technologies, polymer and lipid, which have been established for many years.

There are drugs based on polymer, there are drugs that are based on lipids. Up until now, no one has done or combined the two in the way that we have done, under a self-assembly condition, a self-assembly manner. We are creating a matrix of thousands of alternate layers. Think about the structure of an onion or a book, where the polymer are the backbone of this matrix, and in between, you have the drug surrounded by lipids, no chemical bond between the compound, just a matrix organized into the structure. Once the drug is released or applied in the tumor site and the incision site, gradually the drug is released layer by layer at the site, covering the area, in our case, the incision, for 30 days of antibiotic, of protection of the drug from infection.